Original language | English (US) |
---|---|
Pages (from-to) | 99-110 |
Number of pages | 12 |
Journal | Global heart |
Volume | 10 |
Issue number | 2 |
DOIs | |
State | Published - 2015 |
ASJC Scopus subject areas
- Epidemiology
- Community and Home Care
- Cardiology and Cardiovascular Medicine
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Reducing Premature Cardiovascular Morbidity and Mortality in People With Atherosclerotic Vascular Disease The World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease. / Perel, Pablo; Avezum, Alvaro; Huffman, Mark et al.
In: Global heart, Vol. 10, No. 2, 2015, p. 99-110.Research output: Contribution to journal › Editorial › peer-review
TY - JOUR
T1 - Reducing Premature Cardiovascular Morbidity and Mortality in People With Atherosclerotic Vascular Disease The World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease
AU - Perel, Pablo
AU - Avezum, Alvaro
AU - Huffman, Mark
AU - Pais, Prem
AU - Rodgers, Anthony
AU - Vedanthan, Raj
AU - Wood, David
AU - Yusuf, Salim
N1 - Funding Information: Dr. Perel lead several studies on preventive cardiology for which his institution has received grants. He has no conflicts related to this particular article. Dr. Huffman received grant support from the World Heart Federation for its Emerging Leaders program, which has been supported by unrestricted educational grants from AstraZeneca, Boehringer Ingelheim, and Bupa. Dr. Rodgers's employer The George Institute for Global Health obtained an exclusive global license in December 2012 for polypills used in clinical trials it conducted, following a decision by Dr. Reddy's Ltd. not to proceed with taking the products to market because of uncertainty in regulatory requirements. Dr. Wood lead several studies on preventive cardiology for which his institution has received grants from both peer review organizations as well as from a number of pharmaceutical companies. He has also received honoraria for lectures and travel expenses for talks. He has no conflicts related to this particular article. Dr. Yusuf lead several trials with a range of drugs as well as lifestyle interventions involving CVD prevention for which his institution has received grants from both peer review organizations as well as from a number of pharmaceutical companies. He has also received honoraria for lectures and travel expenses for talks. He has no conflicts related to this particular article. The remaining authors report no relationships that could be construed as a conflict of interest.
PY - 2015
Y1 - 2015
UR - http://www.scopus.com/inward/record.url?scp=84948991519&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84948991519&partnerID=8YFLogxK
U2 - 10.1016/j.gheart.2015.04.003
DO - 10.1016/j.gheart.2015.04.003
M3 - Editorial
C2 - 26213297
AN - SCOPUS:84948991519
SN - 2211-8160
VL - 10
SP - 99
EP - 110
JO - CVD Prevention and Control
JF - CVD Prevention and Control
IS - 2
ER -